Matrix metalloproteinase-2 polymorphisms and clinical outcome of Chinese patients with nonsmall cell lung cancer treated with first-line, platinum-based chemotherapy

Cancer

Volumn 118, Issue 14, 2012, Pages 3587-3598

  Zhao, Xueying ^a   Wang, Xun ^b   Wu, Wenting ^a,c   Gao, Zhiqiang ^d   Wu, Junjie ^e   Garfield, David H ^f   Wang, Haijian ^a   Wang, Jiucun ^a   Qian, Ji ^a   Li, Huan ^a   Jin, Li ^a   Li, Qiang ^e   Han, Baohui ^d   Lu, Daru ^a   Bai, Chunxue ^b  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SHANGHAI JIAO TONG UNIVERSITY   (China)

^e SECOND MILITARY MEDICAL UNIVERSITY   (China)

^f ProMed Cancer Centers   (China)

Author keywords

clinical outcome; matrix metalloproteinase 2; nonsmall cell lung cancer; platinum based chemotherapy; polymorphism

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; GELATINASE A; GEMCITABINE; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CHINESE; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; FEMALE; GASTROINTESTINAL TOXICITY; GENE; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HAPLOTYPE; HOMOZYGOTE; HUMAN; INOPERABLE CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MMP 2 GENE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PHARMACOGENETICS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84863299462     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26669     Document Type: Article

References (46)

1. Shiraishi K, Kohno T, Tanai C, et al. Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol. 2010; 28: 4945-4952.
2. Wu W, Zhang W, Qiao R, et al. Association of XPD polymorphisms with severe toxicity in non-small cell lung cancer patients in a Chinese population. Clin Cancer Res. 2009; 15: 3889-3895.
3. Han B, Gao G, Wu W, et al. Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients. Lung Cancer. 2011; 72: 238-243.
4. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 2129-2139. (Pubitemid 38637993)
5. van Erp NP, Eechoute K, van der Veldt AA, et al. Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol. 2009; 27: 4406-4412.
6. Liu CY, Chen PM, Chiou TJ, et al. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Cancer. 2008; 112: 1932-1940.
7. Werb Z,. ECM and cell surface proteolysis: regulating cellular ecology. Cell. 1997; 91: 439-442. (Pubitemid 27508232)
8. Chetty C, Bhoopathi P, Lakka SS, Rao JS,. MMP-2 siRNA induced Fas/CD95-mediated extrinsic II apoptotic pathway in the A549 lung adenocarcinoma cell line. Oncogene. 2007; 26: 7675-7683. (Pubitemid 350224224)
9. McQuibban GA, Gong JH, Wong JP, Wallace JL, Clark-Lewis I, Overall CM,. Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood. 2002; 100: 1160-1167. (Pubitemid 34864266)
10. Janowska-Wieczorek A, Marquez LA, Nabholtz JM, et al. Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34(+) cells and their transmigration through reconstituted basement membrane. Blood. 1999; 93: 3379-3390. (Pubitemid 29220905)
11. Chetty C, Rao JS, Lakka SS,. Matrix metalloproteinase pharmacogenomics in non-small-cell lung carcinoma. Pharmacogenomics. 2011; 12: 535-546.
12. Overall CM, Kleifeld O,. Tumour microenvironment-opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006; 6: 227-239. (Pubitemid 43292566)
13. Prenzel N, Zwick E, Daub H, et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature. 1999; 402: 884-888.
14. Zhou Y, Yu C, Miao X, et al. Functional haplotypes in the promoter of matrix metalloproteinase-2 and lung cancer susceptibility. Carcinogenesis. 2005; 26: 1117-1121. (Pubitemid 41214305)
15. Levi E, Fridman R, Miao HQ, Ma YS, Yayon A, Vlodavsky I,. Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc Natl Acad Sci U S A. 1996; 93: 7069-7074. (Pubitemid 26243503)
16. Gearing AJ, Beckett P, Christodoulou M, et al. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature. 1994; 370: 555-557. (Pubitemid 24264920)
17. Clutter SD, Fortney J, Gibson LF,. MMP-2 is required for bone marrow stromal cell support of pro-B-cell chemotaxis. Exp Hematol. 2005; 33: 1192-1200. (Pubitemid 41416967)
18. Haviernik P, Diaz MT, Haviernikova E, Tse W, Stetler-Stevenson WG, Bunting KD,. Hematopoiesis in mice is extremely resilient to wide variation in TIMP/MMP balance. Blood Cells Mol Dis. 2008; 41: 179-187.
19. Heissig B, Hattori K, Dias S, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell. 2002; 109: 625-637. (Pubitemid 34628725)
20. Wang L, Clutter S, Benincosa J, Fortney J, Gibson LF,. Activation of transforming growth factor-beta1/p38/Smad3 signaling in stromal cells requires reactive oxygen species-mediated MMP-2 activity during bone marrow damage. Stem Cells. 2005; 23: 1122-1134. (Pubitemid 41377728)
21. Yu C, Pan K, Xing D, et al. Correlation between a single nucleotide polymorphism in the matrix metalloproteinase-2 promoter and risk of lung cancer. Cancer Res. 2002; 62: 6430-6433. (Pubitemid 35364100)
22. Price SJ, Greaves DR, Watkins H,. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem. 2001; 276: 7549-7558.
23. Qian Q, Wang Q, Zhan P, et al. The role of matrix metalloproteinase 2 on the survival of patients with non-small cell lung cancer: a systematic review with meta-analysis. Cancer Invest. 2010; 28: 661-669.
24. Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S,. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 1998; 58: 1048-1051. (Pubitemid 28182477)
25. Scherf DB, Dally H, Muller P, et al. Single nucleotide polymorphisms in matrix metalloproteinase genes and lung cancer chemotherapy response and prognosis. Eur Respir J. 2010; 35: 381-390.
26. Heist RS, Marshall AL, Liu G, et al. Matrix metalloproteinase polymorphisms and survival in stage I non-small cell lung cancer. Clin Cancer Res. 2006; 12: 5448-5453. (Pubitemid 44497260)
27. Kubben FJ, Sier CF, Meijer MJ, et al. Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer. Br J Cancer. 2006; 95: 744-751. (Pubitemid 44373491)
28. Miao X, Yu C, Tan W, et al. A functional polymorphism in the matrix metalloproteinase-2 gene promoter (-1306C/T) is associated with risk of development but not metastasis of gastric cardia adenocarcinoma. Cancer Res. 2003; 63: 3987-3990. (Pubitemid 36917916)
29. Zhou Y, Yu C, Miao X, et al. Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. Carcinogenesis. 2004; 25: 399-404. (Pubitemid 38344407)
30. Rollin J, Regina S, Vourc'h P, et al. Influence of MMP-2 and MMP-9 promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer. Lung Cancer. 2007; 56: 273-280. (Pubitemid 46591988)
31. Cecchin E, Innocenti F, D'Andrea M, et al. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J Clin Oncol. 2009; 27: 2457-2465.
32. Gabriel SB, Schaffner SF, Nguyen H, et al. The structure of haplotype blocks in the human genome. Science. 2002; 296: 2225-2229. (Pubitemid 34680308)
33. Stephens M, Donnelly P,. A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet. 2003; 73: 1162-1169. (Pubitemid 37414228)
34. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA,. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet. 2002; 70: 425-434. (Pubitemid 34112296)
35. Bi N, Yang M, Zhang L, et al. Cyclooxygenase-2 genetic variants are associated with survival in unresectable locally advanced non-small cell lung cancer. Clin Cancer Res. 2010; 16: 2383-2390.
36. Jacobs EJ, Hsing AW, Bain EB, et al. Polymorphisms in angiogenesis-related genes and prostate cancer. Cancer Epidemiol Biomarkers Prev. 2008; 17: 972-977. (Pubitemid 351536431)
37. Manso H, Krug T, Sobral J, et al. Variants of the matrix metalloproteinase-2 but not the matrix metalloproteinase-9 genes significantly influence functional outcome after stroke [serial online]. BMC Med Genet. 2010; 11: 40.
38. Khan SG, Muniz-Medina V, Shahlavi T, et al. The human XPC DNA repair gene: arrangement, splice site information content and influence of a single nucleotide polymorphism in a splice acceptor site on alternative splicing and function. Nucleic Acids Res. 2002; 30: 3624-3631. (Pubitemid 34919219)
39. van Kuilenburg AB, Meijer J, Mul AN, et al. Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity. Hum Genet. 2010; 128: 529-538.
40. Xiong L, Catoire H, Dion P, et al. MEIS1 intronic risk haplotype associated with restless legs syndrome affects its mRNA and protein expression levels. Hum Mol Genet. 2009; 18: 1065-1074.
41. Saunders R, Deane CM,. Synonymous codon usage influences the local protein structure observed. Nucleic Acids Res. 2010; 38: 6719-6728.
42. Nackley AG, Shabalina SA, Tchivileva IE, et al. Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science. 2006; 314: 1930-1933. (Pubitemid 46026115)
43. Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM,. Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res. 2007; 67: 9609-9612. (Pubitemid 47621204)
44. Clutter SD, Fortney JE, Gibson LF,. Chemotherapy disrupts activity of translational regulatory proteins in bone marrow stromal cells. Exp Hematol. 2006; 34: 1522-1531. (Pubitemid 44566420)
45. Thomas P, Khokha R, Shepherd FA, Feld R, Tsao MS,. Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer. J Pathol. 2000; 190: 150-156. (Pubitemid 30082487)
46. Egeblad M, Werb Z,. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002; 2: 161-174. (Pubitemid 37328786)